Ulcerative colitis (subacute manifestations) - infliximab

1. Guidance

This guidance relates only to the use of infliximab for subacute manifestations of moderately to severely active ulcerative colitis. The guidance does not cover the use of infliximab for acute manifestations of moderately to severely active ulcerative colitis.

1.1. Infliximab is not recommended for the treatment of subacute manifestations of moderately to severely active ulcerative colitis.

1.2. For the purposes of this guidance, a subacute manifestation of moderately to severely active ulcerative colitis is defined as disease that would normally be managed in an outpatient setting and that does not require hospitalisation or the consideration of urgent surgical intervention.